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TABLE 1 ANA Associations With Mortality Outcomes and Cardiovascular Events
Events (n)
Unadjusted
HR (95% CI)
Model 1
HR (95% CI)
Model 2
HR (95% CI)
All-cause mortality 158 1.29 (1.13–1.48) 1.27 (1.10–1.46) 1.26 (1.10–1.46)
p Value 0.0002 0.0008 0.002
Cardiovascular death 54 1.45 (1.17–1.79) 1.42 (1.13–1.77) 1.37 (1.10–1.73)
p Value 0.0006 0.002 0.01
ASCVD 157 1.16 (1.01–1.35) 1.17 (1.01–1.35) 1.18 (1.01–1.37)
p Value 0.04 0.04 0.04
Sensitivity Analysis in Participants With ANA <65 EU
All-cause mortality 145 1.31 (1.07–1.61) 1.28 (1.03–1.58) 1.25 (1.002–1.56)
p Value 0.01 0.02 0.047
Cardiovascular death 50 1.69 (1.19–2.40) 1.62 (1.13–2.30) 1.49 (1.02–2.17)
p Value 0.003 0.009 0.04
ASCVD 148 1.22 (0.99–1.50) 1.23 (1.0–1.51) 1.22 (0.98–1.51)
p Value 0.058 0.054 0.07
N ¼ 2,803. Hazard ratios (HRs) and 95% conﬁdence intervals (CIs) for 1 SD increase in log (ANA).
ANA ¼ antinuclear autoantibodies; ASCVD ¼ atherosclerotic cardiovascular disease; EU ¼ enzyme-linked immunosorbent assay unit(s).
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a population-based assessment of the implications of
low-level ANA.
The DHS is an observational cohort; thus, we
cannot determine whether the association between
ANA and adverse events is causal. These ﬁndings
raise the possibility that the presence of ANA signals
immunological events that are affecting vascular
health, although the exact role requires further study.
Several study limitations are noteworthy. Baseline
ANAwere performed; thus, we cannot account for vari-
ability in ANA or autoimmunity over time. Exclusion
of participants with autoimmune disease was on the
basis of self-report, rather than physician evaluation.
In conclusion, increasing ANA are independently
associated with all-cause mortality, cardiovascular
death, and ASCVD in a representative multiethnic
population-based cohort. ANA may identify in-
dividuals at increased risk of death and ASCVD
independent of traditional risk factors or clinical
autoimmune disease, a ﬁnding that potentially
affects a substantial percent of the population.*Elizabeth Blair Solow, MD
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Joggers Do Not Have
Lower Mortality Rates
Than Strenuous JoggersThe recently published paper by Schnohr et al. (1) on
jogging and long-term mortality concluded that there
was a U-shaped association between all-cause mor-
tality and dose of jogging, and that low-intensity
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2671jogging was more beneﬁcial than high-intensity
jogging. However, this conclusion cannot be drawn
from the data presented.
Schnohr et al. claim to have analyzed the quantity,
frequency, and pace of jogging. However, only fre-
quency was assessed, and instead of quantity and pace,
they assessed time spent jogging and perceived in-
tensity, respectively. A ﬁt person may cover a much
longer distance during the same time as an unﬁt person
and perceive the same absolute intensity as light
instead of strenuous. This is a serious problem, because
cardiorespiratory ﬁtness is strongly related to mortality
and to the analyzed exposures. This confounding was
not taken into account, and adjustment for ﬁtness
could have resulted in the opposite conclusion.
None of the conclusions are justiﬁed by the
statistical analysis. In the analysis of the 3 exposures—
quantity, frequency, and pace of jogging—the conﬁ-
dence intervals of the subgroups overlap, which
means there are no differences between the groups.
Most of the subgroups include only 1 to 5 cases, and
the conclusions based on this few cases cannot be
justiﬁed. An analysis in which all of the jogging groups
are merged could make statistical sense, and it could
conclude that there is a substantial beneﬁt to jogging,
but not how fast, how long, or how frequently jogging
should take place.
The investigators concluded that there is a U-shape
between the dose of jogging and mortality. The deﬁ-
nition of what is light, moderate, and strenuous
jogging is problematic, because the study did not
assess these exposures, as previously mentioned. The
strenuous group experienced only 2 deaths, and to
draw conclusions of a U-shape on the basis of 2 cases
cannot be justiﬁed. The investigators do not describe
how the 413 joggers in the reference group were
selected from among the 3,950 nonjoggers, but it
is obvious that an age difference of approximately
20 years between the reference group and all sub-
groups of joggers points to a severe selection bias,
which makes a comparison difﬁcult.
Finally, it is surprising that the investigators did
not discuss in detail why 2 recently published studies
that analyzed walking (2) and cycling (3) from the
same data came up with the opposite conclusion in
relation to intensity and duration of physical activity.*Lars Bo Andersen, Dr Med Sci
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Jogging Pace
What Makes the Difference?We appreciate the ﬁndings reported by Schnohr et al.
(1), but we feel that insufﬁcient attention has been
paid to the consequences of pace categorization
by self-reporting. The investigators demonstrate a
U-shaped relationship between the dose of jogging
and all-cause mortality. Joggers were categorized as
light, moderate, or strenuous joggers on the basis of
the quantity of jogging and the self-reported pace
(slow, average, fast). The use of the self-reported
(perceived) pace makes sense from a practical and
clinical point of view, but it is unjustiﬁed to assign
ﬁxed amounts of miles per hour to the pace cate-
gories without considering individual ﬁtness levels.
Everybody will agree that a pace of 7 mph will
generate different cardiovascular responses and will
be perceived differently by a 35-year-old elite runner
than an 85-year-old amateur runner due to the huge
differences in aerobic power (cardiovascular ﬁtness)
(2). Thus, the U-shaped association between the dose
of jogging and mortality is likely to be true when
based on the individually perceived pace, but is very
likely wrong when based on absolute values. In our
opinion, this is a critical point, because a pace of 7
mph is fast for a novice or an amateur runner but is a
perceived slower pace for an elite runner. Profes-
sional endurance athletes usually perform >80% of
their training sessions at light intensities (50% to
70% of their maximal heart rate) (3), and therefore,
would be rated as moderate or even light joggers
according to the categorization applied by Schnohr
et al. (1). This is compared with novice runners who
often train at too high intensities. Furthermore,
numerous middle-aged and poorly prepared recrea-
tional runners start strenuous running programs af-
ter cardiovascular disease diagnosis. This means that
